Study of 123I-Iomazenil SPECT for neurobehavioral deficits after traumatic brain injury

Study of 123I-Iomazenil SPECT for neurobehavioral deficits after traumatic brain injury - IMZ-TBI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008095

Enrollment

Registered

2012-06-04

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurobehavioral deficits after traumatic brain injury

Interventions

Injection of Benzodine (123I-Iomazenil) and acquisition of SPECT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with neurobehavioral deficits after traumatic brain injury, in whom diffuse axonal injury is the central feature accoding to history of the accident, symptom, and CT/MRI not accompanying severe contusion, hematoma, and other pathologies. 6-60 months after the brain injury.

Exclusion criteria

Exclusion criteria: Those who need to continue Benzodiazepines without interruption for 1 week. Those who perform neuropsychological tests. Those who have a history of mental or neurologiocal disorders before the brain injury. Those in whom PTSD were strongly suspected. Those with hypopituitarism. Left-handed Those who are in dispute or are very likely to dispute because of the brain injury.

Design outcomes

Primary

Measure	Time frame
Detectability of diffuse axonal injury with 123I-Iomazenil SPECT	—

Countries

Japan

Contacts

Public ContactEtsuro Mori

Tohoku university graduate school of medicine Department of behavioral neurology and cognitive neuroscience

morie@med.tohoku.ac.jp022-717-7356

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026